瑞加德松的全合成研究(3)
[3] Zablocki J， Palle V， Blackburn B， et al. 2-Substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor [J]. Nucleosides Nucleotides Nucleic Acids， 2001， 20(4-7)： 343-360.
[4] Grisenti P， Shahrzad PE， Guazzi G， et al. Stable solid forms of regadenoson： WO2014167046A1[P]. 2014-10-16.
[5] Linden JM， Sullivan GW， Scheld WM. Method compositions for treating inflammatory response： US6514949[P]. 2003-02-04.
[6] Ma C， Nadji S， Wooldridge LT. Improved processes for the preparation of regadenoson and a new crystalline form thereof： WO2012149196A1[P]. 2012-11-02.
[7] Montgomery JA， Holum LB. Synthesis of potential anticancer agents. Ⅲ. Hydrazino analogs of biologically active purines[J]. J Am Chem Soc， 1957， 79(9)： 2185-2188.
[8] Lieu H， Blackburn B， Belardinelli L. Methods and compositions for increasing patient tolerability during myocardial imaging methods： US20090081120A1[P]. 2009-03-26.
[9] Kvapil L， Hradil P， Grepl M， et al. Polymorph of 2-[4-[(methylamino) carbonyl]-1H-pyrazol-1-yl] adenosine： US20140323712A1[P]. 2014-10-30., http://www.100md.com(刘伟 罗剑飞 张志刚)
[4] Grisenti P， Shahrzad PE， Guazzi G， et al. Stable solid forms of regadenoson： WO2014167046A1[P]. 2014-10-16.
[5] Linden JM， Sullivan GW， Scheld WM. Method compositions for treating inflammatory response： US6514949[P]. 2003-02-04.
[6] Ma C， Nadji S， Wooldridge LT. Improved processes for the preparation of regadenoson and a new crystalline form thereof： WO2012149196A1[P]. 2012-11-02.
[7] Montgomery JA， Holum LB. Synthesis of potential anticancer agents. Ⅲ. Hydrazino analogs of biologically active purines[J]. J Am Chem Soc， 1957， 79(9)： 2185-2188.
[8] Lieu H， Blackburn B， Belardinelli L. Methods and compositions for increasing patient tolerability during myocardial imaging methods： US20090081120A1[P]. 2009-03-26.
[9] Kvapil L， Hradil P， Grepl M， et al. Polymorph of 2-[4-[(methylamino) carbonyl]-1H-pyrazol-1-yl] adenosine： US20140323712A1[P]. 2014-10-30., http://www.100md.com(刘伟 罗剑飞 张志刚)